» Articles » PMID: 15221804

Predictability of FTY720 Efficacy in Experimental Autoimmune Encephalomyelitis by in Vivo Macrophage Tracking: Clinical Implications for Ultrasmall Superparamagnetic Iron Oxide-enhanced Magnetic Resonance Imaging

Overview
Date 2004 Jun 29
PMID 15221804
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To examine the efficacy of FTY720 as a new agent to reduce inflammatory activity in an animal model of multiple sclerosis (MS) by in vivo macrophage tracking.

Material And Methods: FTY720 was used for treatment of rats in a model of chronic relapsing experimental autoimmune encephalomyelitis (EAE) at an oral dose of 0.3 mg/kg/day. Magnetic resonance imaging (MRI) based on in vivo tracking of macrophages labeled with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, immunohistological staining (IHC), and neurological readouts was used to study the burden of disease in treated and untreated animals.

Results: While untreated animals showed severe paralysis of the hind paws, intense accumulation of macrophages in brain tissue, and areas of blood-brain barrier (BBB) disruption, FTY720-treated animals displayed no signs of inflammatory activity or neurological impairment. These observations were made for both acute phase and first relapse.

Conclusion: Tracking of macrophages by MRI provides direct evidence of the immunomodulatory efficacy of FTY720 in the EAE model and correlates well with neurological symptoms and histology.

Citing Articles

The sphingosine-1-phosphate signaling pathway (sphingosine-1-phosphate and its receptor, sphingosine kinase) and epilepsy.

Wang L, Kong Q, Leng X, Leung H, Li Y Epilepsia Open. 2024; 10(1):55-73.

PMID: 39727628 PMC: 11803289. DOI: 10.1002/epi4.13112.


Machine learning assisted-nanomedicine using magnetic nanoparticles for central nervous system diseases.

Tomitaka A, Vashist A, Kolishetti N, Nair M Nanoscale Adv. 2023; 5(17):4354-4367.

PMID: 37638161 PMC: 10448356. DOI: 10.1039/d3na00180f.


Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.

Thomas A, Barkhof F, Bulte J Radiology. 2022; 303(3):486-497.

PMID: 35471110 PMC: 9131169. DOI: 10.1148/radiol.211252.


Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.

Pournajaf S, Dargahi L, Javan M, Pourgholami M Front Pharmacol. 2022; 13:807639.

PMID: 35250559 PMC: 8889014. DOI: 10.3389/fphar.2022.807639.


PET imaging of P2XR in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [C]SMW139.

Beaino W, Janssen B, Kooijman E, Vos R, Schuit R, OBrien-Brown J J Neuroinflammation. 2020; 17(1):300.

PMID: 33054803 PMC: 7556947. DOI: 10.1186/s12974-020-01962-7.